A. Mira

How to manage KRAS G12C-mutated advanced non-small-cell lung cancer

G. Metro, L. Cantini, B. Ricciuti, 2022, Drugs in context.

Four individually druggable MET hotspots mediate HGF-driven tumor progression.

Natalie de Jonge, C. Blanchetot, Els Festjens, 2014, The Journal of clinical investigation.

Exploiting orthologue diversity for systematic detection of gain-of-function phenotypes

C. Isella, E. Medico, L. Fu, 2008, BMC Genomics.

Met-driven invasive growth involves transcriptional regulation of Arhgap12

A. Bertotti, E. Medico, L. D'Alessandro, 2008, Oncogene.

The GAB 2 signaling scaffold promotes anchorage independence and drives a transcriptional response associated to metastatic progression of breast cancer

E Medico, C. Isella, E. Medico, 2022 .

Stroma-derived HGF drives metabolic adaptation of colorectal cancer to angiogenesis inhibitors

R. Mangues, P. Comoglio, T. Perera, 2017, Oncotarget.

A non-dividing cell population with high pyruvate dehydrogenase kinase activity regulates metabolic heterogeneity and tumorigenesis in the intestine

M. Rivera, R. Sadreyev, A. Sapino, 2022, Nature Communications.

Comparative analysis and isoform-specific therapeutic vulnerabilities of KRAS mutations in non-small cell lung cancer.

A. Redig, P. Jänne, D. Santamaría, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

The GAB2 signaling scaffold promotes anchorage independence and drives a transcriptional response associated with metastatic progression of breast cancer

C. Isella, E. Medico, D. Cantarella, 2009, Oncogene.

YAP and TAZ orchestrate adaptive resistance to KRAS inhibitors

C. Ambrogio, A. Mira, 2023, Nature Cancer.